The Cooper Companies, Inc. Common Stock (COO) — 分析摘要
The Cooper Companies, Inc. Common Stock(COO)的市值为10.56十亿美元,最近一年的营收同比增长了+5.1%。净利润率为9.2%。当前市盈率为18.5倍。
核心要点
- 营收同比变化+5.1%
- 净利润率9.2%
- 市盈率18.5倍
与OPHTHALMIC GOODS板块的其他公司相比,COO的营收增长为+5.1%,市盈率为18.5倍。
The Cooper Companies, Inc. Common Stock (COO)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示无重大红旗
基于最新财报,没有触发重大的信用、利润率或趋势红旗。
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
行业
OPHTHALMIC GOODS
员工人数
15,000
总部
SAN RAMON, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.06
股息收益率
0.11%
股息历史
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。